MediPrint Ophthalmics has reported encouraging results from its Phase 2b clinical trial for LL-BMT1, a 3D-printed contact lens that elutes bimatoprost and hyaluronic acid to manage mild to moderate glaucoma. The data, presented by Ian Ben Gaddie, OD, FAAO, at the American Academy of Optometry’s annual meeting, indicate that the lens achieved its primary endpoints while offering significant advantages over traditional eyedrops, the company said in a press release. 

The study demonstrated that LL-BMT1, in a 32-µg dose, achieved equivalent IOP reduction to bimatoprost 0.01% drops. Patients required only 6 insertions over 3 weeks, representing an 86% reduction in treatment frequency compared to daily drop administration. This delivery method could address patient adherence issues common in glaucoma care.

In addition to managing IOP, the lenses improved dry eye symptoms by 40% and enhanced comfort by 38%, which investigators attributed to their hyaluronic acid component. Safety data showed no serious adverse events, confirming tolerability for potential long-term use.

MediPrint plans to initiate a Phase 3 trial of LL-BMT1 in 2025 while exploring its use in daily disposable lenses for dry eye relief, the company said in the press release.